Ajanta Pharma Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2025, declared Interim Dividend of Rs. 28 per equity share.
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ajanta Pharma's board, meeting on November 3, 2025, declared a 1st interim dividend of Rs. 28 per equity share on a face value of Rs. 2, totaling a payout of about Rs. 349.82 crore. The record date is fixed as November 10, 2025, with payment on or after November 20, 2025. For Q2 FY26, consolidated revenue grew 14% year-on-year to Rs. 1,354 crore, while profit after tax rose 20% to Rs. 260 crore; EBITDA was Rs. 328 crore (up 5%), though it included a Rs. 41 crore mark-to-market forex loss. For H1 FY26, revenue rose 14% to Rs. 2,656 crore and PAT climbed 12% to Rs. 516 crore, with healthy ROCE of 30% and RONW of 25%. The US generics segment led growth, jumping 48% in Q2 and 42% in H1. The company also flagged that Income Tax Authorities conducted search operations at certain premises in August 2025, with no formal communication received yet and no adjustments made.
Healthy double-digit earnings growth and a sizable dividend payout signal strong cash generation and shareholder-friendly policy. However, the unresolved Income Tax search in August 2025 is a pending overhang that investors should monitor for any further developments.